Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 9, 2009
Cambridge, MA, Sepetember 9, 2009 - A paper underscoring the importance of protein methyltransferases (PMTs) in drug discovery is published in the September 2009 online issue of NATURE REVIEWS DRUG DISCOVERY. Scientists Dr. Robert A. Copeland and Dr. Victoria M. Richon from Epizyme, Inc. in their paper entitled "Protein methyl...
Oct 7, 2009
Cambridge, MA, October 7, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the closing of a $32 million Series B financing led by new investor Bay City Capital (BCC). Joining BCC as new investors are Amgen Ventures and As...
Oct 20, 2009
Cambridge, MA, October 20, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today that Dr. Hoyoung Huh, President and CEO of BiPar Sciences, Inc., was appointed Epizyme's Chairman of the Board of Directors. Epizyme recently ann...
Dec 8, 2009
Cambridge, MA, December 8, 2009 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M. Epizyme initially announced a $32M ro...
Mar 24, 2010
Cambridge, MA, March 24, 2010 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceuticals, announced today the appointment of Robert Gould, Ph.D. as Chief Executive Officer and of Jason Rhodes as Executive Vice President and Chief Business Officer. Dr. Gould h...
May 14, 2010
Cambridge, MA, May 14, 2010 - Epizyme, Inc. announced today the appointment of Mikel Moyer, Ph.D., as Vice President of Molecular Discovery. He joins Epizyme from the Broad Institute, where he was Director of Medicinal Chemistry in the Stanley Center for Psychiatric Research. Prior to the Broad, Dr. Moyer held leadership posi...
Jul 16, 2010
Cambridge, MA, July 16, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme...
Nov 3, 2010
Cambridge, MA, November 3, 2010 - Epizyme, Inc., a company leading the discovery and development of first‐in‐class, targeted cancer therapeutics against epigenetic targets, today announced that it has been awarded $733,437 in grants under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants are for t...
Nov 15, 2010
Cambridge, MA, November 15, 2010 - Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, today announced the publication of breakthrough new research in the Proceedings of the National Academy of Sciences (USA). The discovery, center...
Nov 23, 2010
Cambridge, MA, November 23, 2010 - Epizyme, Inc., a company creating personalized therapeutics based on breakthrough discoveries in the field of epigenetics, announced that data related to the Company’s programs will be the subject of multiple oral presentations at the 52nd American Society of Hematology (ASH) Annual Mee...
Jan 6, 2011
NORWALK, Conn. – January 6, 2011 - The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of...
Jan 10, 2011
Cambridge, MA, January 10, 2011 – Epizyme today announced a worldwide strategic alliance with GlaxoSmithKline (GSK) to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases (HMTs), an important class of epigenetic enzymes, for the treatment of cancer and other diseases. ...
Feb 10, 2011
Cambridge, MA, February 10, 2011 - Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in three upcoming conferences being held during February. ...
Mar 10, 2011
Cambridge, MA, March 10, 2011 - Epizyme, Inc. announced today a worldwide partnership with Eisai Co., Ltd., Tokyo, Japan to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients. Under the terms of the agreement, Ep...
Apr 27, 2011
Cambridge, MA, April 27, 2011 - Epizyme, Inc., a leader in the creation of personalized therapeutics based on breakthrough discoveries in the field of epigenetics, announced today the company has been identified as the #1 company nationwide in The Scientist's ...
Page:
...
Next Last
 
= add release to Briefcase